SCHEMBL20969712

SCHEMBL20969712

COc1ccc(CCN(c2nc3cc(F)c(F)c(F)c3s2)C(C)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.46
FFAR1 O14842 1/20 0.39
TAS2R14 Q9NYV8 6/20 0.39
LPAR1 Q92633 4/20 0.38
LPAR5 Q9H1C0 4/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
PTGER4 P35408 1/20 0.37
MMP10 P09238 2/20 0.36
MMP8 P22894 2/20 0.36
MMP13 P45452 2/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
UTS2R Q9UKP6 1/20 0.35
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
ALOX5 P09917 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969619 0.91 KARS1 (0.46) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969571 0.90 KARS1 (0.46) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969659 0.88 KARS1 (0.46) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969622 0.88 KARS1 (0.47) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969690 0.87 KARS1 (0.45) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969671 0.87 KARS1 (0.50) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969719 0.86 KARS1 (0.44) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969725 0.84 KARS1 (0.64) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969737 0.84 KARS1 (0.46) KARS1FFAR1TAS2R14LPAR1LPAR5
SCHEMBL20969634 0.83 KARS1 (0.51) KARS1FFAR1TAS2R14LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885FFAR1 2815/4885TAS2R14 1971/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885FFAR1 2815/4885TAS2R14 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.